- Home
- ALXO vs ANVS Comparison
ALXO vs ANVS Comparison
Compare ALXO & ANVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ALXO | ANVS |
|---|---|---|
| Founded | 2015 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 68.3M | 111.3M |
| IPO Year | 2020 | 2019 |
Fundamental Metrics
Financial Performance| Metric | ALXO | ANVS |
|---|---|---|
| Price | $2.14 | $2.56 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 2 |
| Target Price | $3.42 | ★ $13.50 |
| AVG Volume (30 Days) | ★ 872.5K | 314.1K |
| Earning Date | 06-01-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 31.02 | ★ 62.92 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.41 | $1.11 |
| 52 Week High | $2.66 | $5.50 |
Technical Indicators
Market Signals| Indicator | ALXO | ANVS |
|---|---|---|
| Relative Strength Index (RSI) | 51.04 | 46.37 |
| Support Level | $2.01 | $2.27 |
| Resistance Level | $2.27 | $2.63 |
| Average True Range (ATR) | 0.23 | 0.20 |
| MACD | -0.06 | 0.03 |
| Stochastic Oscillator | 19.23 | 33.85 |
Price Performance
Historical ComparisonAbout ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
About ANVS Annovis Bio Inc.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.